Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025)

Regeneron Pharmaceuticals has reported Operating Leases for 4 years, with the latest figure at $986.8 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Leases rose 3.39% year-over-year to $986.8 million; the trailing twelve-month figure through Dec 2025 stood at $986.8 million (up 3.39% YoY), and the FY2025 full-year result was $986.8 million, up 3.39% from the prior year.
• Operating Leases for Q4 2025 stood at $986.8 million, up from $954.4 million in the prior quarter.
• The five-year high for Operating Leases was $986.8 million in Q4 2025, with the low at $788.2 million in Q4 2022.
• Average Operating Leases over 4 years is $884.3 million, with a median of $881.0 million recorded in 2023.
• Year-over-year, Operating Leases rose 2.47% in 2023 and climbed 18.16% in 2024.
• Tracing REGN's Operating Leases over 4 years: stood at $788.2 million in 2022, then rose by 2.47% to $807.7 million in 2023, then rose by 18.16% to $954.4 million in 2024, then grew by 3.39% to $986.8 million in 2025.
• The last three Operating Leases figures came in at $986.8 million (Q4 2025), $954.4 million (Q4 2024), and $807.7 million (Q4 2023), per Business Quant data.

Peer Comparison